{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:06:59Z","timestamp":1791896819418,"version":"4.3.4"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Generalized anxiety disorder (GAD) is a chronic and disabling condition. Although cognitive behavioral therapy (CBT) is a first-line treatment for GAD, access to this treatment is limited; digital CBT (DCBT) programs may have the potential to overcome barriers to effective treatment and expand therapist reach and impact.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the effectiveness of smartphone-delivered DCBT compared with an active psychoeducation control condition for the treatment of GAD.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This single-blind, parallel-group, decentralized randomized clinical trial with 1:1 allocation was conducted between March 8, 2023, and February 28, 2024. Procedures for this fully remote national study were conducted through Boston University. Participants were adults aged 22 years or older who scored 15 or higher on the 7-item Generalized Anxiety Disorder (GAD-7) scale and met diagnostic criteria for current GAD.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n A self-directed, tailored DCBT for GAD designed to be used flexibly for efficient learning of CBT techniques via smartphone. The control condition was an online psychoeducation intervention.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Primary outcomes were remission status as determined by a blinded independent evaluator (assessed with the Clinical Global Impressions\u2013Improvement [CGI-I] scale) and self-reported anxiety symptom severity (assessed with the GAD-7), evaluated at the primary end point at 10 weeks and the secondary end point at 24 weeks.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 351 adults were randomized (175 DCBT, 176 psychoeducation; mean [SD] age, 40.6 [10.9] years; 259 [73.8%] women). Significantly lower GAD-7 scores were found for DCBT (Cohen\n d<\/jats:italic>\n , 1.09 [95% CI, 0.81-1.37] at week 10 and 0.96 [95% CI, 0.67-1.24] at week 24). Additionally, 103 of 145 DCBT participants (71.0%) met remission status (assessed by the CGI-I) at 10 weeks compared with 54 of 156 psychoeducation participants (34.6%) (odds ratio [OR], 4.63; 95% CI, 2.85-7.54;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001); remission occurred in 115 of 148 participants (77.7%) for DCBT and 78 of 150 (52.0%) for psychoeducation at 24 weeks (OR, 3.22; 95% CI, 1.95-5.32;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial, DCBT provided significant and sustained benefits to adults with GAD. Given the limitations in access to empirically supported CBT, an efficacious DCBT program has clear potential for public health benefit.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT05748652<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.48884","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:30:58Z","timestamp":1765816258000},"page":"e2548884","source":"Crossref","is-referenced-by-count":3,"title":["Digital Cognitive Behavioral Treatment for Generalized Anxiety Disorder"],"prefix":"10.1001","volume":"8","author":[{"given":"E. Marie","family":"Parsons","sequence":"first","affiliation":[{"name":"Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tali","family":"Ball","sequence":"additional","affiliation":[{"name":"Big Health Inc, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Carl","sequence":"additional","affiliation":[{"name":"Big Health Inc, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair L.","family":"Henry","sequence":"additional","affiliation":[{"name":"Big Health Inc, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Emsley","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Miller","sequence":"additional","affiliation":[{"name":"Big Health Inc, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen Y.","family":"Wong","sequence":"additional","affiliation":[{"name":"Big Health Inc, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Coombs","sequence":"additional","affiliation":[{"name":"Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Collins","sequence":"additional","affiliation":[{"name":"Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca Chis","family":"Ster","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper A. J.","family":"Smits","sequence":"additional","affiliation":[{"name":"Department of Psychology, The University of Texas at Austin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Otto","sequence":"additional","affiliation":[{"name":"Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"issue":"6","key":"zoi251313r2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","article-title":"Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"zoi251313r3","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.janxdis.2009.07.011","article-title":"Quality of life impairment in generalized anxiety disorder, social phobia, and panic disorder.","volume":"23","author":"Barrera","year":"2009","journal-title":"J Anxiety Disord"},{"issue":"3","key":"zoi251313r4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.31887\/DCNS.2015.17.3\/bbandelow","article-title":"Epidemiology of anxiety disorders in the 21st century.","volume":"17","author":"Bandelow","year":"2015","journal-title":"Dialogues Clin Neurosci"},{"issue":"5","key":"zoi251313r5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/da.20249","article-title":"Impairment and quality of life in individuals with generalized anxiety disorder.","volume":"24","author":"Henning","year":"2007","journal-title":"Depress Anxiety"},{"issue":"2","key":"zoi251313r6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jad.2011.11.014","article-title":"Humanistic and economic burden of generalized anxiety disorder in North America and Europe.","volume":"140","author":"Revicki","year":"2012","journal-title":"J Affect Disord"},{"issue":"9","key":"zoi251313r8","first-page":"617","article-title":"Diagnosis and management of generalized anxiety disorder and panic disorder in adults.","volume":"91","author":"Locke","year":"2015","journal-title":"Am Fam Physician"},{"issue":"1","key":"zoi251313r9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/16506073.2018.1560358","article-title":"Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta-analysis of randomized controlled trials.","volume":"49","author":"Carl","year":"2020","journal-title":"Cogn Behav Ther"},{"key":"zoi251313r10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.janxdis.2017.10.001","article-title":"Systematic review and meta-analysis of dropout rates in individual psychotherapy for generalized anxiety disorder.","volume":"52","author":"Gersh","year":"2017","journal-title":"J Anxiety Disord"},{"issue":"3","key":"zoi251313r11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/jamapsychiatry.2019.3986","article-title":"Long-term outcomes of cognitive behavioral therapy for anxiety-related disorders: a systematic review and meta-analysis.","volume":"77","author":"van Dis","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"zoi251313r12","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1080\/j.1440-1614.2004.01423.x","article-title":"Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder.","volume":"38","author":"Heuzenroeder","year":"2004","journal-title":"Aust N Z J Psychiatry"},{"issue":"7","key":"zoi251313r13","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s10597-018-0252-x","article-title":"A preliminary exploration of the barriers to delivering (and receiving) exposure-based cognitive behavioral therapy for anxiety disorders in adult community mental health settings.","volume":"54","author":"Wolitzky-Taylor","year":"2018","journal-title":"Community Ment Health J"},{"issue":"2","key":"zoi251313r14","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.cpr.2009.11.001","article-title":"Dissemination of cognitive-behavioral treatments for anxiety disorders: overcoming barriers and improving patient access.","volume":"30","author":"Gunter","year":"2010","journal-title":"Clin Psychol Rev"},{"issue":"3","key":"zoi251313r15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/wps.20673","article-title":"The efficacy of app-supported smartphone interventions for mental health problems: a meta-analysis of randomized controlled trials.","volume":"18","author":"Linardon","year":"2019","journal-title":"World Psychiatry"},{"issue":"12","key":"zoi251313r16","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/da.23079","article-title":"Efficacy of digital cognitive behavioral therapy for moderate-to-severe symptoms of generalized anxiety disorder: a randomized controlled trial.","volume":"37","author":"Carl","year":"2020","journal-title":"Depress Anxiety"},{"issue":"2","key":"zoi251313r17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1017\/S0033291708003498","article-title":"A meta-analytic review of the effects of psychotherapy control conditions for anxiety disorders.","volume":"39","author":"Smits","year":"2009","journal-title":"Psychol Med"},{"issue":"1","key":"zoi251313r18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1741-7015-7-79","article-title":"Psychoeducation for depression, anxiety and psychological distress: a meta-analysis.","volume":"7","author":"Donker","year":"2009","journal-title":"BMC Med"},{"issue":"2","key":"zoi251313r19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4103\/0976-500X.72352","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.","volume":"1","author":"Schulz","year":"2010","journal-title":"J Pharmacol Pharmacother"},{"key":"zoi251313r20","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"zoi251313r21","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7.","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med"},{"key":"zoi251313r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbtep.2020.101609","article-title":"Feasibility and efficacy of a digital CBT intervention for symptoms of generalized anxiety disorder: a randomized multiple-baseline study.","volume":"70","author":"Miller","year":"2021","journal-title":"J Behav Ther Exp Psychiatry"},{"issue":"3","key":"zoi251313r25","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/16506073.2011.582138","article-title":"Psychometric comparison of the Generalized Anxiety Disorder Scale-7 and the Penn State Worry Questionnaire for measuring response during treatment of generalised anxiety disorder.","volume":"40","author":"Dear","year":"2011","journal-title":"Cogn Behav Ther"},{"issue":"6","key":"zoi251313r26","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/j.1365-2753.2007.00921.x","article-title":"The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use.","volume":"14","author":"Berk","year":"2008","journal-title":"J Eval Clin Pract"},{"issue":"1","key":"zoi251313r27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1744-859X-12-2","article-title":"A structured interview guide for global impressions: increasing reliability and scoring accuracy for CNS trials.","volume":"12","author":"Targum","year":"2013","journal-title":"Ann Gen Psychiatry"},{"issue":"9","key":"zoi251313r28","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure.","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"issue":"3","key":"zoi251313r29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004183","article-title":"The Sleep Condition Indicator: a clinical screening tool to evaluate insomnia disorder.","volume":"4","author":"Espie","year":"2014","journal-title":"BMJ Open"},{"issue":"2","key":"zoi251313r31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1037\/fsh0000493","article-title":"Anxiety interventions delivered in primary care behavioral health routine clinical practice.","volume":"38","author":"Shepardson","year":"2020","journal-title":"Fam Syst Health"},{"issue":"6","key":"zoi251313r33","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/15402002.2016.1163703","article-title":"Prevalence of insomnia and associated factors in outpatients with generalized anxiety disorder treated in psychiatric clinics.","volume":"15","author":"Ferre Navarrete","year":"2017","journal-title":"Behav Sleep Med"},{"issue":"3","key":"zoi251313r34","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/da.23113","article-title":"Co-morbidity between mood and anxiety disorders: a systematic review and meta-analysis.","volume":"38","author":"Saha","year":"2021","journal-title":"Depress Anxiety"},{"issue":"4","key":"zoi251313r35","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1037\/0022-006X.61.4.611","article-title":"Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder.","volume":"61","author":"Borkovec","year":"1993","journal-title":"J Consult Clin Psychol"},{"issue":"1","key":"zoi251313r36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.psychres.2012.03.045","article-title":"The Pittsburgh Sleep Quality Index in older primary care patients with generalized anxiety disorder: psychometrics and outcomes following cognitive behavioral therapy.","volume":"199","author":"Bush","year":"2012","journal-title":"Psychiatry Res"},{"issue":"4","key":"zoi251313r37","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0887-6185(03)00031-8","article-title":"Insomnia and generalized anxiety disorder: effects of cognitive behavior therapy for GAD on insomnia symptoms.","volume":"18","author":"B\u00e9langer","year":"2004","journal-title":"J Anxiety Disord"},{"issue":"1","key":"zoi251313r38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1080\/10503307.2023.2286992","article-title":"Adverse events in psychotherapy randomized controlled trials: a systematic review.","volume":"35","author":"Klatte","year":"2025","journal-title":"Psychother Res"},{"issue":"1","key":"zoi251313r39","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/10503307.2024.2301972","article-title":"Negative effects in randomized controlled trials of psychotherapies and psychological interventions: a systematic review.","volume":"35","author":"Honkalampi","year":"2025","journal-title":"Psychother Res"},{"issue":"1","key":"zoi251313r40","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41746-024-01388-y","article-title":"Systematic review and meta-analysis of adverse events in clinical trials of mental health apps.","volume":"7","author":"Linardon","year":"2024","journal-title":"NPJ Digit Med"},{"issue":"1","key":"zoi251313r42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190554","article-title":"Mobile and traditional cognitive behavioral therapy programs for generalized anxiety disorder: a cost-effectiveness analysis.","volume":"13","author":"Kumar","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"zoi251313r43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmen.0000116","article-title":"Cost-effectiveness of automated digital CBT (Daylight) for generalized anxiety disorder: a Markov simulation model in the United States.","volume":"1","author":"Darden","year":"2024","journal-title":"PLoS Ment Health"},{"key":"zoi251313r1","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5th ed"},{"key":"zoi251313r30","volume-title":"Stata. Release 18","year":"2023"},{"key":"zoi251313r7","unstructured":"National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults: management. NICE clinical guideline No. 113. Published January 26, 2011. Updated June 15, 2020. Accessed January 23, 2025. https:\/\/www.nice.org.uk\/guidance\/cg113\/resources\/generalised-anxiety-disorder-and-panic-disorder-in-adults-management-pdf-35109387756997"},{"key":"zoi251313r22","unstructured":"US Food and Drug Administration. Pediatric medical devices. Accessed November 10, 2025. https:\/\/www.fda.gov\/medical-devices\/products-and-medical-procedures\/pediatric-medical-devices"},{"key":"zoi251313r24","unstructured":"Big Health. Daylight Rx: the first FDA-cleared, reimbursable anxiety treatment. Accessed November 10, 2025. https:\/\/www.bighealth.com\/daylight-rx"},{"key":"zoi251313r32","unstructured":"National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults: management. Clinical guideline 113. Published January 26, 2011. Updated June 15, 2020. Accessed January 23, 2025. https:\/\/www.nice.org.uk\/guidance\/cg113\/chapter\/Recommendation"},{"key":"zoi251313r41","unstructured":"United States Census Bureau. QuickFacts. Accessed January 16, 2025. https:\/\/www.census.gov\/quickfacts\/fact\/table\/US\/PST045224"},{"key":"zoi251313r44","unstructured":"Centers for Medicare & Medicaid Services. Calendar year (CY) 2025 Medicare Physician Fee Schedule final rule. November 1, 2024. Accessed August 7, 2025. https:\/\/www.cms.gov\/newsroom\/fact-sheets\/calendar-year-cy-2025-medicare-physician-fee-schedule-final-rule"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2842818\/parsons_2025_oi_251313_1765214658.71111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:31:01Z","timestamp":1765816261000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2842818"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.48884","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]}}}